articleTop 1% cited
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Nature Immunology · 2001 · Vol. 2(3) · pp. 261–268
Yvette Latchman✉(Brigham and Women's Hospital)Clive R. WoodTatyana Chernova(Harvard University)Divya ChaudharyMadhuri Borde(Brigham and Women's Hospital)Irene Chernova(Harvard University)Yoshiko Iwai(Kyoto University)Andrew J. LongJulia A. Brown(Harvard University)Raquel Nunes(Harvard University)Edward Greenfield(Dana-Farber Cancer Institute)Karen BourqueVassiliki A. Boussiotis(Dana-Farber Cancer Institute)Laura CarterBeatriz M. CarrenoNelly Malenkovich(Harvard University)Hiroyuki Nishimura(Kyoto University)Taku Okazaki(Kyoto University)Tasuku Honjo(Kyoto University)Arlene H. Sharpe(Brigham and Women's Hospital)Gordon J. Freeman(Harvard University)
Cancer Immunotherapy and BiomarkersImmune Cell Function and InteractionT-cell and B-cell ImmunologyT-cell receptorCD28T cellCell biologyCytokinePD-L1ReceptorChemistryBiologyCancer research
MeSH terms
Molecular Sequence DataAmino Acid SequenceAnimalsAntigens, SurfaceBlood ProteinsCells, CulturedCricetinaeHumansLigandsLymphocyte ActivationMembrane GlycoproteinsMice, Inbred BALB CPeptidesReceptors, Antigen, T-CellT-Lymphocytes
Funding
- Wellcome Trust
- National Institutes of Health
Citations
2,931
FWCI
25.09
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
Cited by
Immune checkpoints and their inhibition in cancer and infectious diseases
European Journal of Immunology · 2017 · 533 citations
PD-1 and Its Ligands in Tolerance and Immunity
Annual Review of Immunology · 2008 · 5,272 citations
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Clinical Cancer Research · 2005 · 789 citations
Role of the PD-1 Pathway in the Immune Response
American Journal of Transplantation · 2012 · 427 citations
THE B7 FAMILY REVISITED
Annual Review of Immunology · 2005 · 2,279 citations
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Clinical Cancer Research · 2007 · 895 citations
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Journal of Cellular Physiology · 2018 · 506 citations
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Clinical Cancer Research · 2009 · 812 citations
References
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
The EMBO Journal · 1992 · 3,162 citations
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine · 1999 · 2,463 citations
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Immunity · 1999 · 2,706 citations
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Immunity · 1995 · 2,880 citations
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
The Journal of Experimental Medicine · 2000 · 5,184 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.